Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
- 1 May 1999
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (5) , 479-482
- https://doi.org/10.1046/j.1365-2125.1999.00954.x
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1995
- Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosisThe American Journal of Cardiology, 1995
- Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.Heart, 1994
- Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.Hypertension, 1994
- Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1993
- Anti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary HyperaldosteronismJournal of Molecular and Cellular Cardiology, 1993
- Aldosterone reduces baroreceptor discharge in the dog.Hypertension, 1992
- Circadian Variation in the Frequency of Onset of Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Beneficial Effects of Vagal Stimulation and Bradycardia During Experimental Acute Myocardial IschemiaCirculation, 1974
- Ectopic arrhytmia provoking action of aldosteroneLife Sciences, 1962